Thyroid cancer

Source: Wikipedia, the free encyclopedia.

Thyroid cancer
Five year survival rates 98% (US)[5]
Frequency3.2 million (2015)[6]
Deaths31,900 (2015)[7]

Thyroid cancer is

throat due to mass effect from the tumor. However, most cases are asymptomatic.[1][10] Cancer can also occur in the thyroid after spread from other locations, in which case it is not classified as thyroid cancer.[4]

Risk factors include

fine needle aspiration.[1] Screening people without symptoms and at normal risk for the disease is not recommended.[10][11]

Treatment options may include

Five-year survival rates are 98% in the United States.[5]

Globally as of 2015, 3.2 million people have thyroid cancer.

Filipino females.[13] Rates have increased in the last few decades, which is believed to be due to better detection.[12] In 2015, it resulted in 31,900 deaths.[7]

Signs and symptoms

Most people with thyroid cancer do not have symptoms at the time of diagnosis and thyroid nodules and thyroid cancer is usually found incidentally on imaging of the neck.[10][14] Up to 65% of adults have small nodules in their thyroids, but typically under 10% of these nodules are found to be cancerous.[15] Sometimes, the first sign is an enlarged lymph node. Later symptoms that can be present are pain in the anterior region of the neck and changes in voice due to an involvement of the recurrent laryngeal nerve.[16]

Thyroid cancer is usually found in a

Thyroid nodules are of particular concern when they are found in those under the age of 20. The presentation of benign nodules at this age is less likely, thus the potential for malignancy is far greater.[17]

Causes

Thyroid cancers are thought to be related to a number of environmental and genetic predisposing factors, but significant uncertainty remains regarding their causes.[18]

Environmental exposure to

Fukushima, Kyshtym, and Windscale[20] nuclear disasters.[21] Thyroiditis and other thyroid diseases also predispose to thyroid cancer.[20][22]

Genetic causes include multiple endocrine neoplasia type 2, which markedly increases rates, particularly of the rarer medullary form of the disease.[23] Mutations in the genes for MenA and Men2B in multiple endocrine neoplasia is responsible for 25% of medullary thyroid cancers.[10]

Diagnosis

Further information: Thyroid nodule
papillary thyroid carcinoma

After a

Bethesda system.[29]

After diagnosis, to understand potential for spread of disease, or for follow up monitoring after surgery, a whole body I-131 or I-123 radioactive iodine scan may be performed.[30]

In adults without symptoms, screening for thyroid cancer is not recommended.[31]

Classification

Pie chart of thyroid cancer types by incidence.[32]

Thyroid cancers can be classified according to their

histopathological characteristics.[33][34]
These variants can be distinguished (distribution over various subtypes may show regional variation):

The follicular and papillary types together can be classified as "differentiated thyroid cancer".[40] These types have a more favorable prognosis than the medullary and undifferentiated types.[41]

  • Papillary microcarcinoma is a subset of papillary thyroid cancer defined as a nodule measuring less than or equal to 1 cm.[42] 43% of all thyroid cancers and 50% of new cases of papillary thyroid carcinoma are papillary microcarcinoma.[43][44] Management strategies for incidental papillary microcarcinoma on ultrasound (and confirmed on FNAB) range from total thyroidectomy with radioactive iodine ablation to lobectomy or observation alone. Harach et al. suggest using the term "occult papillary tumor" to avoid giving patients distress over having cancer. Woolner et al. first arbitrarily coined the term "occult papillary carcinoma", in 1960, to describe papillary carcinomas ≤ 1.5 cm in diameter.[45]

Staging

Cancer staging is the process of determining the extent of the development of a cancer. The TNM staging system is usually used to classify stages of cancers, but not of the brain.[46]

  • Stage M1 thyroid cancer
    Stage M1 thyroid cancer
  • Stage N1a thyroid cancer
    Stage N1a thyroid cancer
  • Stage N1b thyroid cancer
    Stage N1b thyroid cancer
  • Stage T1a thyroid cancer
    Stage T1a thyroid cancer
  • Stage T1b thyroid cancer
    Stage T1b thyroid cancer
  • Stage T2 thyroid cancer
    Stage T2 thyroid cancer
  • Stage T3 thyroid cancer
    Stage T3 thyroid cancer
  • Stage T4a thyroid cancer
    Stage T4a thyroid cancer
  • Stage T4b thyroid cancer
    Stage T4b thyroid cancer

Metastases

Detection of differentiated thyroid cancer metastases may be detected by performing a full-body scintigraphy using iodine-131.[47][48]

Spread

Thyroid cancer can spread directly, via lymphatics or blood. Direct spread occurs through infiltration of the surrounding tissues. The tumor infiltrates into

Cervical lymph nodes become palpable in papillary carcinoma even when the primary tumor is unpalpable. Deep cervical nodes, pretracheal, prelaryngeal, and paratracheal groups of lymph nodes are often affected. The lymph node affected is usually the same side as that of the location of the tumor. Blood spread is also possible in thyroid cancers, especially in follicular and anaplastic carcinoma. The tumor emboli do angioinvasion of lungs; end of long bones, skull, and vertebrae are affected. Pulsating metastases occur because of their increased vascularity.[49]

Treatment

Thyroidectomy and dissection of central neck compartment is the initial step in treatment of thyroid cancer in the majority of cases.[14] Thyroid-preserving operations may be applied in cases, when thyroid cancer exhibits low biological aggressiveness (e.g. well-differentiated cancer, no evidence of lymph-node metastases, low MIB-1 index, no major genetic alterations like BRAF mutations, RET/PTC rearrangements, p53 mutations etc.) in patients younger than 45 years.[50] If the diagnosis of well-differentiated thyroid cancer (e.g. papillary thyroid cancer) is established or suspected by

FNA, then surgery is indicated.[50][51] Surgical resection is the preferred treatment for all biopsy confirmed thyroid cancers. In those with very low risk tumors (such as small papillary tumors without evidence of local or metastatic spread or concerning cytologic findings), patients at high surgical risk due to medical problems, those with short expected lifespans or patients with serious medical issues precluding surgery, an active surveillance approach, in which the tumor is monitored over time (such as with serial imaging) may be pursued.[52]

Post surgical monitoring for recurrence or metastasis may include routine ultrasound, CT scans, FDG-PET/CT, radioactive iodine whole body scans, and routine laboratory blood tests for changes in thyroglobulin, thyroglobulin antibodies, or calcitonin, depending on the subtype of thyroid cancer.[53][54][55]

Radioactive iodine-131 is used in people with papillary or follicular thyroid cancer for ablation of residual thyroid tissue after surgery and for the treatment of thyroid cancer.[56] Post-surgical radioactive iodine is recommended for those with high risk of cancer recurrence. Post-surgery radioactive iodine does not reduce recurrence in those with low risk thyroid cancer.[10] Patients with medullary, anaplastic, and most Hurthle-cell cancers do not benefit from this therapy.[14] External irradiation may be used when the cancer is unresectable, when it recurs after resection, or to relieve pain from bone metastasis.[14]

Sorafenib and lenvatinib are approved for advanced metastatic thyroid cancer.[57] Numerous agents are in phase II and III clinical trials.[57]

Prognosis

The prognosis of thyroid cancer is related to the type of cancer and the stage at the time of diagnosis. For the most common form of thyroid cancer, papillary, the overall prognosis is excellent with 97%, 95%, and 90% 10, 15 and 20 year overall survival respectively.[58] The 5 year survival of all thyroid cancers, with treatment, is 98%.[10]

Many small thyroid cancers (mostly papillary type) rarely grow or metastasize. Some have stated that thyroid cancers are

overdiagnosed and will rarely cause symptoms, illness, or death, even without treatment.[59] Low grade thyroid cancer is very commonly seen during autopsy studies, with the person dying from other causes.[59] Increasingly, small thyroid nodules are discovered as incidental findings on imaging (CT scan, MRI, ultrasound) performed for another purpose. Few of these people with incidentally discovered, subclinical thyroid cancers will ever have any symptoms, and overtreatment may be present.[59]

Thyroid cancer is three times more common in women than in men.

5-year survival rate for thyroid cancer is 85% for females and 74% for males.[61]

The identification of some molecular or DNA abnormalities has led to the development of therapies that target these molecular defects. The first of these agents to negotiate the approval process is

vascular endothelial growth factor receptor, and the epidermal growth factor receptor.[62]
For differentiated thyroid carcinoma, strategies are evolving to use selected types of targeted therapy to increase radioactive iodine uptake in papillary thyroid carcinomas that have lost the ability to concentrate iodide. This strategy would make possible the use of radioactive iodine therapy to treat "resistant" thyroid cancers.

Mitogen-activated protein kinase (MAPK) variants are the most common genetic variants seen in thyroid cancer.[10] The BRAF 600E genetic variant is seen in 60% of papillary thyroid cancers. It is associated with increased risks of cervical lymph node metastasis, blunted response to radioactive iodine, and increased rates of local recurrence.[10] RasGTPase mutations are seen in 13% of papillary and 25-50% of follicular cancers and are associated with increased risk of vascular invasion and higher response to radioactive iodine.[10]

Prognosis is better in younger people than older ones.[61]

Prognosis depends mainly on the type of cancer and

cancer stage.[10]

 
Thyroid cancer type		 5-year survival 10-year survival
Stage I Stage II Stage III Stage IV Overall Overall
Papillary 100%[63] 100%[63] 93%[63] 51%51%[63] 96%[64] or 97%[65] 93%[64]
Follicular 100%[63] 100%[63] 71%[63] 50%[63] 91%[64] 85%[64]
Medullary 100%[63] 98%[63] 81%[63] 28%[63] 80%,[64] 83%[66] or 86%[67] 75%[64]
Anaplastic (always stage IV)[63] 7%[63] 7%[63] or 14%[64] (no data)

Epidemiology

Thyroid cancer, in 2010, resulted in 36,000 deaths globally up from 24,000 in 1990.[68] Obesity may be associated with a higher incidence of thyroid cancer, but this relationship remains the subject of much debate.[69]

Thyroid cancer accounts for less than 1% of cancer cases and deaths in the UK. Around 2,700 people were diagnosed with thyroid cancer in the UK in 2011, and around 370 people died from the disease in 2012.[70]

However, in South Korea, thyroid cancer was the 5th most prevalent cancer, which accounted for 7.7% of new cancer cases in 2020.[71]

The incidence of thyroid cancer in the United States increased by 313% from a 1974-1977 incidence of 4.6 cases per 100,000 people to 14.4 cases per 100,000 people in 2010-13.[72] This increase is thought to be due to more widespread use of head and neck imaging (which may incidentally detect thyroid masses) as well as increased use of fine needle aspiration biopsies.[10]

Notable cases

References

  1. ^ a b c d e f g h i j "Thyroid Cancer Treatment". National Cancer Institute. 27 April 2017. Archived from the original on 15 July 2017. Retrieved 18 July 2017.
  2. ^
    PMID 24274180
    .
  3. ^
    PMID 34915752
    .
  4. ^ a b c d e f "Thyroid Cancer Treatment". National Cancer Institute. 12 May 2017. Archived from the original on 16 July 2017. Retrieved 18 July 2017.
  5. ^ a b c d "Cancer of the Thyroid - Cancer Stat Facts". seer.cancer.gov. Archived from the original on 15 July 2017. Retrieved 18 July 2017.
  6. ^
    PMID 27733282
    .
  7. ^
    PMID 27733281
    .
  8. ^ "Cancer Fact sheet N°297". World Health Organization. February 2014. Archived from the original on 29 December 2010. Retrieved 10 June 2014.
  9. ^ "Defining Cancer". National Cancer Institute. 17 September 2007. Archived from the original on 25 June 2014. Retrieved 10 June 2014.
  10. ^
    doi:10.1001/jama.2023.26348
    .
  11. S2CID 205091526
    .
  12. ^
    ISBN 978-9283204299
    .
  13. S2CID 244033542
    .
  14. ^
    ISBN 978-1-891483-62-2. Archived from the original
    on 28 February 2010.
  15. S2CID 5042725
    .
  16. ^ "Thyroid Cancer". Herbert Irving Comprehensive Cancer Center (HICCC) - New York. 1 February 2021. Archived from the original on 5 February 2023. Retrieved 5 February 2023.
  17. ISSN 1759-5029
    .
  18. ^ "Thyroid Cancer Overview - Signaling Pathway. Diagnosis. Targeted Therapy - Creative Biolabs". www.creativebiolabs.net. Archived from the original on 5 February 2023. Retrieved 5 February 2023.
  19. ^ "Radioactive I-131 from Fallout". National Cancer Institute. Archived from the original on 19 May 2014. Retrieved 9 June 2014.
  20. ^
    PMID 8431362
    .
  21. ^ "Experts link higher incidence of children's cancer to Fukushima radiation". ScienceAlert. 12 October 2015. Archived from the original on 19 January 2016. Retrieved 15 January 2016.
  22. PMID 20555084
    .
  23. ^ "Genetics of Endocrine and Neuroendocrine Neoplasias". National Cancer Institute. 1 January 1980. Archived from the original on 4 July 2014. Retrieved 9 June 2014.
  24. PMID 31559190
    .
  25. ^ "TIRADS calculator with free report generator!". radathand.com. 18 June 2024. Retrieved 30 January 2025.
  26. S2CID 21514672
    .
  27. ^ "Thyroid scan: MedlinePlus Medical Encyclopedia". medlineplus.gov. Archived from the original on 27 January 2021. Retrieved 5 February 2021.
  28. ^ "Vol 7 Issue 6 p.3-4". American Thyroid Association. Archived from the original on 4 December 2020. Retrieved 5 February 2021.
  29. PMID 24294568
    .
  30. S2CID 22871325
    .
  31. S2CID 205091526
    .
  32. PMID 30264938.{{cite journal}}: CS1 maint: DOI inactive as of November 2024 (link
    )
  33. ^ "Thyroid Cancer Treatment". National Cancer Institute. 1 January 1980. Archived from the original on 21 April 2008. Retrieved 22 December 2007.
  34. ^ "Thyroid cancer". National Cancer Institute. Archived from the original on 20 December 2007. Retrieved 22 December 2007.
  35. ^
    ISBN 978-1-4160-2973-1
    . 8th edition.
  36. PMID 23477346
    .
  37. S2CID 24129533
    .
  38. S2CID 25818628
    .
  39. ^ "Anaplastic Thyroid Cancer". Columbia Thyroid Center. Archived from the original on 23 December 2019. Retrieved 30 March 2020.
  40. S2CID 7912705. Archived
    from the original on 20 May 2013.
  41. S2CID 11825588
    .
  42. S2CID 23121159
    .
  43. PMID 26870138
    .
  44. PMID 21268762
    .
  45. PMID 13845950
    .
  46. ^ "Cancer Staging - NCI". www.cancer.gov. 9 March 2015. Archived from the original on 19 March 2015. Retrieved 5 February 2023.
  47. PMID 17914109
    .
  48. PMID 3183748
    .
  49. ISBN 978-8190568128
    .
  50. ^
    PMID 19860577
    .
  51. ISBN 9781860163098. Archived from the original
    (PDF) on 26 December 2011. Retrieved 12 July 2013.
  52. hdl:11365/1011394
    .
  53. PMID 26462967
    .
  54. PMID 25810047
    .
  55. PMID 23130564
    .
  56. PMID 24989897
    .
  57. ^
    PMID 29399330
    .
  58. PMC 5801380
    .
  59. ^
    ISBN 978-0-8070-2200-9
    .
  60. ^ "Thyroid Cancer". MedicineNet.com. Archived from the original on 20 October 2011. Retrieved 26 October 2011.
  61. ^
    ISBN 978-3-540-22309-2
    .
  62. ^ "FDA approves new treatment for rare form of thyroid cancer" (Press release). U.S. Food and Drug Administration. 6 April 2011. Archived from the original on 10 April 2011. Retrieved 7 April 2011.
  63. ^ a b c d e f g h i j k l m n o cancer.org Thyroid Cancer Archived 18 October 2013 at the Wayback Machine By the American Cancer Society. In turn citing: AJCC Cancer Staging Manual (7th ed).
  64. ^
    ISBN 978-3-540-22309-2
    . (Note:Book also states that the 14% 10-year survival for anaplastic thyroid cancer was overestimated)
  65. ^ Rounded up to nearest natural number from 96.7% as given by Santacroce L, Gagliardi S, Kennedy AS (28 September 2010). "Thyroid, Papillary Carcinoma". eMedicine. Archived from the original on 28 July 2010.
  66. PMID 16091497
    .
  67. ^ "Medullary Thyroid Cancer". National Cancer Institute. 4 February 2016. Archived from the original on 30 May 2016. Retrieved 11 May 2016.
  68. S2CID 1541253
    .
  69. PMID 25214234. Archived
    from the original on 11 November 2014.
  70. ^ "Thyroid cancer statistics". Cancer Research UK. Archived from the original on 17 October 2014. Retrieved 28 October 2014.
  71. ^ "Republic of Korea Cancer Rates" (PDF). Global Cancer Observatory (GCO). World Health Organization. 2020. Archived (PDF) from the original on 11 November 2022. Retrieved 5 February 2022.
  72. PMC 8216772
    .
  73. ^ "Callum Ainley: Grimsby Town midfielder diagnosed with thyroid cancer". BBC Sport. 16 January 2024. Retrieved 17 January 2024.
  74. ^ Hunsley, James (27 January 2023). "'I am so grateful' - ex-Liverpool midfielder Emre Can opens up on battle with cancer". Goal.com. Archived from the original on 28 January 2023. Retrieved 29 January 2023.
  75. ^ Bamberger, Michael (27 May 2002). "Survivors". Sports Illustrated. Archived from the original on 1 March 2014. Retrieved 11 August 2013.
  76. ^ "Uhm Jung-hwa had Thyroid cancer op". The Korean Herald. 20 October 2010. Archived from the original on 5 February 2022. Retrieved 5 February 2022.
  77. ^ "Lee Moon-se risks cancer relapse to keep singing". The Korean Herald. 31 March 2015.
  78. ^ Lane C (8 September 2005). "Rehnquist Eulogies Look Beyond Bench". The Washington Post. Archived from the original on 4 March 2016. Retrieved 11 May 2016.
  79. ^ "Celebrities with Thyroid problems". Alexander Shifrin. Archived from the original on 26 August 2013. Retrieved 11 August 2013.
Wikimedia Commons has media related to Thyroid cancer.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Thyroid_cancer&oldid=1273646669"